Nuclidium
Nuclidium AG is a clinical-stage Swiss radiopharmaceutical company developing copper-based theranostics (Copper-61 diagnostics and Copper-67 therapeutics on the CuTrace™ platform) for cancer indications including prostate, breast and neuroendocrine tumors, targeting hospital nuclear medicine departments globally.
- Company typePrivate
- Founded2017
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nuclidium does
Nuclidium AG is a clinical-stage biotechnology company headquartered in Basel, Switzerland with an R&D subsidiary in Munich, Germany, founded in 2017 by CEO Dr. Leila Jaafar-Thiel. The company develops copper-based radiopharmaceuticals for cancer diagnosis and therapy, built on its proprietary CuTrace™ platform which pairs Copper-61 (a 3.3-hour half-life positron emitter for PET diagnostics) with Copper-67 (a 2.58-day half-life beta-emitter for therapy) on the same targeting ligand, enabling true theranostics with identical biodistribution between diagnostic and therapeutic agents. Its pipeline comprises four programs: NU101/NuriPro (PSMA-targeted, metastatic castration-resistant prostate cancer), NU201/TraceNET (SSTR2 antagonist, metastatic breast cancer and neuroendocrine tumors), and Kalios (FAP inhibitor, breast and lung cancer), with Phase 1/2 results reported in 2025 and Phase 1/2a therapeutic trials planned for 2026.
The business model is pre-commercial: revenue is expected to be generated through sales of 61Cu-based diagnostic PET imaging agents and 67Cu-based therapeutic radiopharmaceuticals to hospital nuclear medicine departments, supplemented by licensing/royalty arrangements and a manufacturing/supply network. To de-risk commercialization and global distribution, Nuclidium has built a multi-region production footprint — cyclotron-based 61Cu production through PharmaLogic in the US and LinaThera in Medical Valley Forchheim, Germany — and entered a strategic partnership with Guerbet for manufacturing, clinical trial support and commercialization. The company raised approximately CHF 105 million (EUR ~115 million) in Series B financing (July 2025 plus May 2026 extension) from a syndicate including Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, Neva SGR and the EIB co-investment facility Aurea, supplemented by grants from Innosuisse and the European Innovation Council. Its go-to-market is enterprise field sales targeting major hospital systems and academic medical centers with nuclear medicine departments.
Nuclidium firmographics
Firmographics- Name
- Nuclidium
- Legal name
- Nuclidium AG
- Website
- https://nuclidium.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nuclidium AG is a clinical-stage Swiss radiopharmaceutical company developing copper-based theranostics (Copper-61 diagnostics and Copper-67 therapeutics on the CuTrace™ platform) for cancer indications including prostate, breast and neuroendocrine tumors, targeting hospital nuclear medicine departments globally.
- Ownership category
- akta.pro rank
Nuclidium industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where Nuclidium is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
Nuclidium business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Radiopharmaceutical Products: NUCLIDIUM develops and commercializes copper-based radiopharmaceuticals for cancer diagnosis and treatment. Revenue will be generated through sales of diagnostic PET imaging agents (61Cu-based) and therapeutic radiopharmaceuticals (67Cu-based) to hospitals and nuclear medicine centers.
- Licensing and Partnership Agreements: Strategic partnerships with companies like Guerbet and PharmaLogic for manufacturing, distribution, and clinical development support. May include milestone payments and royalties from licensed technology.
- Manufacturing and Supply Network: Revenue generated through global production and manufacturing network for diagnostics and therapeutics, serving hospital workflows with copper-based radiopharmaceuticals.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Nuclidium product offering
Product offeringCore offering
Nuclidium AG is a clinical-stage biotechnology company that develops copper-based radiopharmaceutical theranostics for cancer diagnosis and treatment. Using its proprietary CuTrace™ platform, the company pairs Copper-61 (diagnostic) with Copper-67 (therapeutic) on identical tumor-targeting molecules, enabling true theranostic pairs for prostate, breast, neuroendocrine, and FAP-expressing tumors. Products are designed for cyclotron-based production without nuclear reactors and are supplied to hospitals and nuclear medicine centers globally.
Product overview
Nuclidium is a clinical-stage radiopharmaceutical company pioneering next-generation copper-based radiotheranostics. The company's CuTrace platform enables true theranostics by combining copper isotopes (Copper-61 for diagnostics and Copper-67 for therapeutics) with tumor-specific targeting molecules. The pipeline includes: NU101 (NuriPro) for PSMA-positive metastatic castration-resistant prostate cancer, NU201 for metastatic breast cancer, TraceNET for neuroendocrine tumors, and Kalios for FAP-expressing epithelial tumors. Individual products include 61Cu-NuriPro and 61Cu-TraceNET diagnostics, along with their corresponding 67Cu therapeutics. The company operates in Switzerland and Germany with manufacturing partnerships in Europe and North America.
Differentiator
Problem solved
Functional benefit
Brands
- CuTrace: Proprietary technology platform utilizing copper radionuclides combined with tumour-specific molecules for targeted radiotherapy and diagnostics
- NuriPro
- TraceNET
- Kalios
- NU101
- NU201
Products and services
- NU101 / NuriPro
- NU201 / TraceNET
- Kalios
- 61Cu-NuriPro (61Cu-NODAGA-PSMA I&T)
- 61Cu-TraceNET ([61Cu]Cu-NODAGA-LM3)
- 67Cu-NuriPro
- 67Cu-TraceNET
Quantifiable outcome
- 61Cu-NuriPro PET visualized additional lesions in 50% of patients not seen with 18F-piflufolastat (FDA-approved standard of care)
- +4 more outcomes
Companies that use Nuclidium
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Nuclidium technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Nuclidium partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered major and core.
- Hoag Memorial Hospital PresbyterianmajorPhase 1 clinical trial site for 61Cu-NuriPro™ diagnostic in PSMA-positive prostate cancer patients. Dr. Gary Ulaner serves as Principal Investigator. Trial conducted at Hoag Molecular Imaging and Therapy Clinic, Newport Beach, California.
- Medical Valley Center ForchheimcoreCollaboration partner in Oberfrankenstiftung-funded project for production facility and clinical development of radionuclide therapies in Bavaria.
- Klinikum BayreuthcoreClinical collaboration partner in Oberfrankenstiftung-funded project for radionuclide therapy production and development.
- Erlangen University HospitalcoreAcademic partner in Oberfrankenstiftung-funded project for clinical development of radionuclide therapies.
- GuerbetmajorStrategic partnership for advancement of NUCLIDIUM's copper-based radiotheranostics. Guerbet provides access to global diagnostic imaging expertise, manufacturing network, and clinical trial capabilities. François Nicolas (SVP R&D) joined NUCLIDIUM Board as observer. Guerbet made strategic, non-exclusive investment.
- LinaTheramajorPartnership for building state-of-the-art integrated manufacturing facility in Medical Valley Forchheim. LinaThera produces medical radionuclides in modularly expandable accelerator facility without nuclear reactors. Project supported by Oberfrankenstiftung funding (€400,000).
- PharmaLogic HoldingsmajorStrategic collaboration for production and clinical supply of 61Cu in the United States. PharmaLogic manufactures radiopharmaceuticals at their facilities including Los Angeles, CA. NUCLIDIUM provides scientific know-how and proprietary technology. First product batch manufactured in 2023.
- University Hospital BaselmajorClinical collaboration for Phase 1 trial with TraceNET™ in neuroendocrine tumors. NETRF Investigator Award shared between NUCLIDIUM and USB. Prof. Melpomeni Fani leads as PI. Clinical-scale production process established at USB.
- Neuroendocrine Tumors Research Foundation (NETRF)coreNETRF Investigator Award recipient for Phase 1 trial with TraceNET™ in neuroendocrine tumors. Award aims to support innovative research to improve NET patient care.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Nuclidium competitors and assessment
Company assessmentDirect peers
- Curium: Curium is a global radiopharmaceutical company producing diagnostic and therapeutic nuclear medicines, including PET tracers. Comparable as both a competitor and potential commercial partner for radiopharma distribution.
- Telix Pharmaceuticals: Telix commercializes Illuccix (Ga-68 PSMA-11) for PSMA PET imaging and is developing therapeutic radiopharmaceuticals. Direct competitor across the PSMA theranostic landscape with commercial-stage products.
- Point Biopharma (acquired by Eli Lilly): Point Bio developed Lu-177 PSMA radioligand therapies for mCRPC and was acquired by Eli Lilly for $1.4B in 2024. Highly comparable as a PSMA radioligand developer and a benchmark for the exit opportunity Nuclidium's NU101 could pursue.
- ITM Isotope Technologies Munich: ITM is a radiopharmaceutical company developing therapeutic and diagnostic radioisotope-based products, including Lu-177-based compounds. Competes in the precision oncology radiopharma space with similar production and distribution infrastructure.
- Lantheus Holdings: Lantheus commercializes Pylarify (18F-piflufolastat), the FDA-approved PSMA PET imaging agent that Nuclidium's 61Cu-NuriPro demonstrated superiority over in Phase 1 trials. Direct competitor in the diagnostic PSMA imaging market.
- Ariceum Therapeutics: Ariceum develops SSTR2 antagonist-based radiopharmaceuticals (acquired from Ipsen), directly overlapping with Nuclidium's TraceNET SSTR2 program. Notably, Nuclidium's CMO Ben Pais previously led clinical development at Ariceum.
Broad incumbents
- Novartis (Pluvicto/Locametz): Novartis commercializes Pluvicto (Lu-177 PSMA-617) and Locametz for mCRPC, directly competing with Nuclidium's NU101 program. As the established radioligand therapy leader with approved products and global launch infrastructure, Novartis represents the primary competitive benchmark.
- Bayer (radiopharma via Algeta/Lantheus partnership): Bayer has invested in radiopharmaceuticals including Xofigo (Ra-223) and partnerships targeting PSMA and other radioligand therapies. As a broad incumbent pharma with significant radiopharma ambitions, Bayer represents both competitor and potential acquirer.
- Bracco Imaging: Bracco is an established diagnostic imaging company with a growing radiopharmaceutical portfolio. Overlaps with Nuclidium in molecular imaging agents and represents a potential commercial partner or acquirer for the diagnostic pipeline.
Emerging players
- Radiopharm Theranostics: Radiopharm Theranostics is a clinical-stage radiopharma developing multiple radiotheranostic assets for oncology, with similar stage and pipeline breadth to Nuclidium. Directly comparable as a peer emerging radiotheranostic platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Nuclidium social profiles
Digital presenceNuclidium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nuclidium leadership team
Management profileNumber of profiles
Profiles14 records
Nuclidium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nuclidium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nuclidium
What does Nuclidium do?
Nuclidium AG is a clinical-stage biotechnology company that develops copper-based radiopharmaceutical theranostics for cancer diagnosis and treatment. Using its proprietary CuTrace™ platform, the company pairs Copper-61 (diagnostic) with Copper-67 (therapeutic) on identical tumor-targeting molecules, enabling true theranostic pairs for prostate, breast, neuroendocrine, and FAP-expressing tumors. Products are designed for cyclotron-based production without nuclear reactors and are supplied to hospitals and nuclear medicine centers globally.
Is Nuclidium a public or private company?
Nuclidium is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nuclidium founded?
Nuclidium was founded in 2017. It employs 1 to 10 people.
Where is Nuclidium based?
Nuclidium is headquartered in Basel, Switzerland, in the Europe region.
How does Nuclidium make money?
Three revenue lines are on record. Radiopharmaceutical Products are the primary driver. The others are licensing and Partnership Agreements and manufacturing and Supply Network.
Who are Nuclidium's main competitors?
Direct peers on record are Curium, Telix Pharmaceuticals, Point Biopharma (acquired by Eli Lilly), ITM Isotope Technologies Munich, Lantheus Holdings and Ariceum Therapeutics. Broad incumbents are Novartis (Pluvicto/Locametz), Bayer (radiopharma via Algeta/Lantheus partnership) and Bracco Imaging. Radiopharm Theranostics is listed as an emerging player.
Does Nuclidium have an API?
No public API is recorded for Nuclidium.
What industry is Nuclidium in?
Nuclidium's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.